• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Differential association between apolipoprotein B and LDL cholesterol and cerebral atherosclerosis according to pre-stroke statin use
To reduce cardiovascular risk, low-density lipoprotein cholesterol (LDL-C) is the primary target of statin treatment, while apolipoprotein B (ApoB) is secondary. We investigated the association between atherosclerotic stenosis and LDL-C or ApoB levels and whether a difference in association exists according to pre-admission statin use in ischemic stroke patients.
Source: Atherosclerosis - March 19, 2023 Category: Cardiology Authors: Minyoul Baik, Hyo Suk Nam, Ji Hoe Heo, Hye Sun Lee, Young Dae Kim Source Type: research

Risk of stroke in genetically verified familial hypercholesterolemia: A prospective matched cohort study
Individuals with familial hypercholesterolemia (FH), causing severely elevated LDL-C, are expected to have a higher risk of ischemic stroke. The risk of hemorrhagic stroke and impact of statin use is however not known. We aimed to investigate the risk of incident total, ischemic and hemorrhagic stroke in individuals with FH compared to controls and to explore the association between cumulative statin use and risk of total stroke in FH.
Source: Atherosclerosis - August 27, 2022 Category: Cardiology Authors: Karianne Svendsen, Thomas Olsen, Kathrine J. Vinknes, Liv J. Mundal, Kirsten B. Holven, Martin P. Bogsrud, Trond P. Leren, Jannicke Igland, Kjetil Retterst øl Source Type: research

Effect of non-adherence of evidence-based medication prescribing on major adverse cardiovascular events among acute coronary syndrome patients
Background and Aims: Combination therapy with evidence-based medicines, including 4 groups of medication: dual antiplatelet, beta-blocker, ACEI /ARB, and statin, could reduce the risk of morbidity and mortality among patients with the acute coronary syndrome (ACS). This retrospective cohort study aimed to compare the risk of major adverse cardiovascular events (MACE) including cardiovascular death, myocardial infarction, unstable angina, and stroke during the first year of discharge between ACS patients received 4 groups and those did not receive at least 1 medication group.
Source: Atherosclerosis - December 1, 2020 Category: Cardiology Authors: S. Chinwong, M. Chommontha, S. Kammanat, A. Phrommintikul, D. Chinwong Source Type: research

Statins and beta blockers - The most frequently encountered potential prescribing omissions in rural Romanian elderly population
Background and Aims: Cardiovascular diseases (ischaemic heart diseases and stroke) are the leading cause of death in Romania, the death rate of ischaemic heart disease being three times higher than in European Union. The aim of this study was to identify potential prescribing omissions (PPOs) and to determine their prevalence based on the STOPP / START v.2, 2015, criteria for patients over the age of 65 years old.
Source: Atherosclerosis - December 1, 2020 Category: Cardiology Authors: V.O. Buda, O. Dalleur, A. Prelipcean, S. Buda, M. Andor, D.E. Baibata, A. Dohou, L. Petrescu, C. Cristescu Source Type: research

Statins reduce major adverse limb events and mortality in patients with peripheral artery disease
Background and Aims: Statins are guideline recommended in patients with peripheral artery disease (PAD) for prevention of cardiovascular events. However, comprehensive meta-data on the impact of statin therapy on major adverse limb events (MALE) in PAD patients have not been reported. We want to investigate the association of statin use with MALE events, all-cause death, cardiovascular death and stroke in these patients.
Source: Atherosclerosis - December 1, 2020 Category: Cardiology Authors: D. Pastori, A. Farcomeni, A. Milanese, F. Del Sole, D. Menichelli, W.R. Hiatt, F. Violi Source Type: research

The protective effect of statins against pressure ulcers in stroke patients: A propensity-score matched study based on a real-world database
Limited information is available regarding the association between statins and pressure ulcers. The purpose of this study is to evaluate the beneficial effects of statins on pressure ulcers in stroke patients.
Source: Atherosclerosis - November 29, 2020 Category: Cardiology Authors: Yu-Chen Huang, Chuen-Chau Chang, Chun-Chieh Yeh, Chao-Shun Lin, Chaur-Jong Hu, Ta-Liang Chen, Chien-Chang Liao Source Type: research

Natural compounds as anti-atherogenic agents: Clinical evidence for improved cardiovascular outcomes
Atherosclerosis, a chronic progressive inflammatory condition characterized by the formation of lipid-laden lesions in arterial walls, is associated with substantial morbidity (including ischaemic stroke and myocardial infarction) and mortality. Risk factors for atherosclerosis are well understood and can be ameliorated by evidence-based and guideline-directed pharmaceutical agents (e.g. the reduction of circulating concentrations of low-density lipoprotein cholesterol by statins). Additionally, many natural products (usually food derivatives) and ‘nutraceuticals’ (pharmaceutical formulations prepared from components o...
Source: Atherosclerosis - November 24, 2020 Category: Cardiology Authors: Peter E. Penson, Maciej Banach Tags: Review article Source Type: research

Effect of initiating statin therapy on long-term outcomes of patients with dyslipidemia after intracerebral hemorrhage
Intracerebral hemorrhage (ICH) has a higher mortality than ischemic stroke. Statin is beneficial for stroke, but high potency statin treatment has been associated with the risk of hemorrhagic stroke. The aim of this study was to assess the impact of initiating statin therapy after ICH on cardiovascular outcomes.
Source: Atherosclerosis - July 10, 2019 Category: Cardiology Authors: Ming-Shyan Lin, Yu-Sheng Lin, Shih-Tai Chang, Po-Chang Wang, Victor Chien-Chia Wu, Wey-Yil Lin, Chang-Min Chung Source Type: research

Associations between statins and coronary artery disease and stroke risks in patients with asthma –chronic obstructive pulmonary disease overlap syndrome: A time-dependent regression study
To determine the effects of statin use on coronary artery disease (CAD) and stroke risks in patients with asthma –chronic obstructive pulmonary disease overlap syndrome (ACOS).
Source: Atherosclerosis - February 11, 2019 Category: Cardiology Authors: Jun-Jun Yeh, Cheng-Li Lin, Chung Y. Hsu, Zonyin Shae, Chia-Hung Kao Source Type: research

Association of statin pretreatment with collateral circulation and final infarct volume in acute ischemic stroke patients: A meta-analysis
Statin pretreatment (SP) is associated with improved outcomes in acute ischemic stroke (AIS) patients. Collateral circulation status and final infarct volume (FIV) are independent predictors of functional outcome in AIS.
Source: Atherosclerosis - January 22, 2019 Category: Cardiology Authors: Konark Malhotra, Apostolos Safouris, Nitin Goyal, Adam Arthur, David S. Liebeskind, Aristeidis H. Katsanos, Jo ão Sargento-Freitas, Marc Ribo, Carlos Molina, Jong-Won Chung, Oh Young Bang, Georgios Magoufis, Ahmad Cheema, Steven J. Shook, Ken Uchino, And Source Type: research

Discontinuing or continuing statin following intracerebral hemorrhage from the view of a national cohort study
Statins improve clinical outcomes in patients with ischemic stroke but there is no evidence of the effect of continuing long-term statin therapy in patients with intracerebral hemorrhage (ICH). The aim of this study was to evaluate the impact of continuing statin after ICH.
Source: Atherosclerosis - August 31, 2018 Category: Cardiology Authors: Chang-Min Chung, Ming-Shyan Lin, Chi-Hung Liu, Tsong-Hai Lee, Shih-Tai Chang, Teng-Yao Yang, Kuo-Li Pan, Yu-Sheng Lin Source Type: research

Treatment of atherosclerosis by traditional Chinese medicine: Questions and quandaries
Atherosclerosis and its complications, such as myocardial infarction and stroke, are the major causes of morbidity and mortality, and development of effective therapeutics for both prevention and treatment of this disease is critically important. Currently, there are many drugs available for atherosclerotic disease, but the lipid-lowering drugs statins are still the first-choice for treatment of hypercholesterolemia, a major risk factor for atherosclerosis. On the other hand, traditional Chinese medicines, mainly Chinese herbal medicines (CHM), have been widely used in China and in other Asian countries for the treatment o...
Source: Atherosclerosis - August 30, 2018 Category: Cardiology Authors: Chuan Wang, Manabu Niimi, Teruo Watanabe, Yanli Wang, Jingyan Liang, Jianglin Fan Tags: Review article Source Type: research

Escaping the atherogenic trap: Preventing LDL fusion and binding in the intima
Low-density lipoprotein (LDL) cholesterol plasma concentrations have served as the target of clinical treatment of atherosclerosis-related diseases since the development of simvastatin three decades ago. Targeting endogenous cholesterol synthesis by the inhibition of β-hydroxy-β-methylglutaryl co-enzyme A (HMG-CoA) reductase, statins have since become a mainstay in the lowering of plasma cholesterol and LDL levels and the improvement of cardiovascular outcomes such as myocardial infarction and stroke.
Source: Atherosclerosis - May 18, 2018 Category: Cardiology Authors: Martin Houde, Miranda Van Eck Tags: Editorial Source Type: research

Strokes, cholesterol and statins: When mortality is an endpoint
The Yi et al. stroke mortality study, with 5.2 million person-years of observation in a representative Korean population cohort with a single baseline total cholesterol (TC) measurement, highlights several important issues [1]. First, the authors note the fact that cholesterol lowering “particularly by statins” does not lower stroke mortality in randomized trials. Second, the fact that 53% of stroke deaths were from hemorrhagic strokes, far surpassing its incidence of about 10–20% in all strokes in many countries [1], and that are mainly nonfatal ischemic strokes.
Source: Atherosclerosis - May 2, 2018 Category: Cardiology Authors: Eddie Vos, Pierre Biron Tags: Correspondence Source Type: research

Total cholesterol and the risk of stroke: A double-edged sword or a blunt knife?
Hypercholesterolemia is a major risk factor for ischemic stroke [1]. Although cholesterol- ‐lowering therapies such as statins have consistently shown reduction in the risk of ischemic stroke, concerns have been raised about the accompanied risk of hemorrhagic stroke, mainly including intracerebral hemorrhage (ICH) [2,3]. Indeed, earlier observational data also suggested low total serum cholesterol (TC) as a risk factor for ICH [4,5]. Hence, would low TC levels have a role in stroke like a double-edged sword, by decreasing the risk of ischemic stroke and increasing the risk of ICH?
Source: Atherosclerosis - January 17, 2018 Category: Cardiology Authors: Luiz S érgio F. de Carvalho Tags: Editorial Source Type: research

Pages: 1  2